Supplementary Figure S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy | Synapse
October 17, 2025
Supplementary Figure S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
Key Points
Blinatumomab shows potential benefit in the consolidation phase of chemotherapy for B-Cell precursor acute lymphoblastic leukemia.
The study design includes specific pre-randomization chemotherapy cycles essential for treatment efficacy.
Analysis of chemotherapy cycles emphasizes the drug's application in managing acute lymphoblastic leukemia.
Understanding the study design aids in recognizing treatment pathways for B-Cell precursor leukemia patients.
Abstract
Figure S2 shows the Study 20120215 Study Design, including the pre-randomization chemotherapy cycles.